MedTrace Logo

Clinical Study of MG-K10 Humanized Monoclonal Antibody Injection in Healthy Adult Subjects

NCT06277284 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2024-08-21

No results posted yet for this study

Summary

Research Topics A randomized, open-label, parallel-group, phase I clinical trial comparing the pharmacokinetics of MG-K10 humanized monoclonal antibody in healthy adults

Conditions

  • Pharmacokinetics

Interventions

DRUG

MG-K10 humanized monoclonal antibody injection (prefilled syringe)

MG-K10 Humanized Monoclonal Antibody Injection

DRUG

MG-K10 humanized monoclonal antibody injection（Penicillin bottle）

MG-K10 humanized monoclonal antibody injection (single injection)

Sponsors & Collaborators

  • The Second Hospital of Anhui Medical University

    collaborator OTHER

  • Shanghai Mabgeek Biotech.Co.Ltd

    lead OTHER_GOV

Principal Investigators

  • Wei Hu, doctor · The Second Hospital of Anhui Medical University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-10-23
Primary Completion
2024-01-26
Completion
2024-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06277284 on ClinicalTrials.gov